Tesamorelin is the best-supported compound in this peptide cluster, but only for a narrow medical purpose. FDA-approved EGRIFTA WR is indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Multiple randomized trials show a meaningful reduction in visceral adipose tissue in that population. The approval does not cover general obesity, bodybuilding or anti-aging, and the label states that tesamorelin is not indicated for weight-loss management. It also carries important warnings involving malignancy, elevated IGF-1, fluid retention, glucose intolerance and hypersensitivity.
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid growth hormone-releasing factor analogue. A modification near the N-terminus makes it more resistant to enzymatic breakdown than natural GHRH. It binds pituitary GHRH receptors, stimulates pulsatile growth hormone release and raises downstream IGF-1.
It is related to sermorelin and CJC-1295 at the pathway level, but it is not interchangeable with either. Tesamorelin has a defined approved formulation, product label and phase 3 evidence base. Similar receptor activity does not allow another GHRH analogue to borrow those results.
The exact FDA-approved indication
The current US prescribing information for EGRIFTA WR says tesamorelin is indicated for reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label also states:
- long-term cardiovascular safety has not been established;
- the medicine is not indicated for weight-loss management;
- there are no data showing improved adherence to antiretroviral therapy.
This distinction protects against a common SEO and marketing error: rewriting "reduces visceral fat in HIV lipodystrophy" as "an approved fat-loss peptide." The patient population, diagnosis and outcome are all narrower.
Lipodystrophy associated with HIV and its treatment can involve disproportionate visceral abdominal fat. That condition is not equivalent to ordinary overweight or obesity, even if waist size looks similar.
What randomized trials found
Phase 3 visceral-fat outcomes
In a 12-month randomized, placebo-controlled study of 404 adults with HIV and excess abdominal fat, tesamorelin reduced visceral adipose tissue by 10.9% over the first six months versus 0.6% with placebo. Waist-related measures and body-image distress improved, while limb fat and abdominal subcutaneous fat did not significantly change.
Participants who continued tesamorelin reached an approximately 18% visceral-fat reduction at 12 months. Those switched to placebo rapidly regained the visceral-fat improvement. This withdrawal finding shows both that the drug had a real treatment effect and that the effect did not persist after treatment stopped.
A pooled analysis of two phase 3 trials included 806 antiretroviral-treated adults. It found a significant visceral-fat reduction and improvements in triglycerides and cholesterol-to-HDL ratio, with the effect maintained among those continuing treatment for 52 weeks.
Liver-fat research
A smaller randomized JAMA study involving 50 adults with HIV and abdominal fat accumulation found reductions in both visceral and liver fat after six months. A later 12-month trial in people with HIV and nonalcoholic fatty liver disease also reported a relative liver-fat reduction.
These are important research findings, but liver-fat reduction is not the current FDA-approved indication. It should be described as investigational evidence rather than established labeling.
| Question | Evidence-based answer |
|---|---|
| Does tesamorelin reduce visceral fat in HIV lipodystrophy? | Yes, supported by randomized phase 3 trials |
| Does it reduce subcutaneous fat everywhere? | No; trials showed relative selectivity for visceral fat |
| Is it a general weight-loss drug? | No; FDA labeling specifically says it is not indicated for weight-loss management |
| Is the effect permanent? | No; visceral fat reaccumulated after treatment withdrawal |
| Is it approved for fatty liver disease? | No; positive studies remain outside the labeled indication |
Why tesamorelin is not proof for other peptides
An approved drug result belongs to the studied active ingredient, formulation, population and indication. It does not validate a clinic's CJC-1295 blend or compounded sermorelin.
CJC-1295 has small healthy-volunteer pharmacology studies and unresolved naming across DAC and non-DAC forms. Sermorelin has historical diagnostic and pediatric use, but its US products were discontinued. Tesamorelin has current labeling and large condition-specific trials. Grouping them as "GHRH peptides" is useful for explaining mechanism, not for merging clinical claims.
Major warnings and precautions
The current EGRIFTA WR label provides a far more developed safety framework than exists for unapproved research peptides.
Malignancy and IGF-1
The label warns that tesamorelin stimulates GH production and increases IGF-1. Active malignancy is a contraindication. For people with a history of treated, stable cancer, the benefits and risks require careful consideration because HIV-positive populations can have elevated baseline malignancy risk.
Persistently elevated IGF-1 may require clinical reassessment. A laboratory number should be interpreted against the approved indication and overall health, not pursued as a performance target.
Glucose intolerance
Tesamorelin can cause glucose intolerance or diabetes. The label calls for evaluation of glucose status before and during therapy and careful assessment if diabetes develops. People with diabetes also require attention to possible retinopathy changes.
Some trials found no clinically meaningful average long-term glucose difference, while a smaller study detected an early fasting-glucose rise. Both can be true: a neutral group mean does not remove individual risk or the need for labeled monitoring.
Fluid retention and hypersensitivity
Fluid retention can cause edema, joint pain and carpal-tunnel-type symptoms. Hypersensitivity and injection-site reactions are also recognized. The product is contraindicated in pregnancy and in people with disruption of the hypothalamic-pituitary axis from conditions such as pituitary surgery, hypopituitarism, head irradiation or pituitary tumors.
These are examples of why an approved prescription medicine still requires diagnosis, contraindication screening and follow-up.
Tesamorelin in Thailand
FDA approval is a US status, not automatic Thai authorization. Use the Thai FDA drug search to verify the exact brand, formulation, importer and current registration. A different vial labeled tesamorelin is not automatically equivalent to EGRIFTA WR or EGRIFTA SV.
For someone with HIV-associated abdominal changes, the relevant care team may include an HIV specialist and an endocrinologist. Useful discussion points include:
- whether the fat distribution meets the labeled clinical context;
- antiretroviral history and alternative causes of abdominal enlargement;
- cancer history and pituitary function;
- baseline glucose status and relevant eye disease;
- the clinically meaningful outcome and follow-up plan.
This is prescription-drug decision-making, not a generic peptide-shopping question.
Competitive sport
Tesamorelin is prohibited at all times under the growth hormone-releasing factors section of the 2026 WADA Prohibited List. An athlete with a legitimate medical indication must follow the applicable therapeutic-use-exemption process. FDA approval does not override anti-doping rules.
Common tesamorelin mistakes
- Dropping "HIV-associated lipodystrophy" from the indication.
- Calling a visceral-fat reduction overall weight loss.
- Promising permanent results despite withdrawal data.
- Presenting fatty-liver findings as an approved indication.
- Transferring tesamorelin trials to CJC-1295 or sermorelin.
- Treating an online vial as equivalent to the labeled product.
- Omitting malignancy, IGF-1, glucose and fluid-retention warnings.
Frequently asked questions
What is tesamorelin FDA approved to treat?
Tesamorelin is FDA approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight-loss management.
Does tesamorelin cause overall weight loss?
It should not be presented as a general weight-loss drug. Its label describes a weight-neutral effect, while trials focused on reducing visceral abdominal fat in a specific HIV population.
Does visceral fat return after tesamorelin is stopped?
Trial extensions found that visceral fat reaccumulated after participants switched from tesamorelin to placebo, so the measured effect was not maintained after discontinuation.
Clinical takeaway
Tesamorelin shows what strong peptide evidence looks like: a characterized medicine, randomized phase 3 trials, a narrow indication and detailed risk labeling. It is a legitimate option for selected adults with HIV-associated lipodystrophy under specialist care, not a general-purpose fat-loss or anti-aging product. Use the peptide evidence hub to compare approval levels and the sermorelin guide to understand why shared GHRH biology does not create shared indications.